{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:17:12Z","timestamp":1792610232106,"version":"4.5.0"},"publisher-location":"Cham","reference-count":71,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783319997155","type":"print"},{"value":"9783319997162","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T00:00:00Z","timestamp":1546214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-3-319-99716-2_4","type":"book-chapter","created":{"date-parts":[[2018,12,30]],"date-time":"2018-12-30T11:33:57Z","timestamp":1546169637000},"page":"83-98","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS)"],"prefix":"10.1007","author":[{"given":"Adetokunbo","family":"Oluwasanjo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saritha","family":"Kartan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onder","family":"Alpdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Gru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley M.","family":"Haverkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Porcu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,31]]},"reference":[{"issue":"9","key":"4_CR1","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1182\/blood-2016-08-692566","volume":"129","author":"A Broccoli","year":"2017","unstructured":"Broccoli A, Zinzani PL (2017) Peripheral T-cell lymphoma, not otherwise specified. Blood 129(9):1103\u20131112","journal-title":"Blood"},{"issue":"7","key":"4_CR2","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/cncr.30416","volume":"123","author":"Kenneth R. Carson","year":"2016","unstructured":"Carson KR et al (2017) A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer 123(7):1174\u20131183","journal-title":"Cancer"},{"issue":"25","key":"4_CR3","doi-asserted-by":"publisher","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","volume":"117","author":"FM Foss","year":"2011","unstructured":"Foss FM et al (2011) Peripheral T-cell lymphoma. Blood 117(25):6756\u20136767","journal-title":"Blood"},{"issue":"25","key":"4_CR4","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J et al (2008) International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124\u20134130","journal-title":"J Clin Oncol"},{"issue":"5","key":"4_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.hoc.2008.07.010","volume":"22","author":"Julie M. Vose","year":"2008","unstructured":"Vose JM (2008) Peripheral T-cell non-Hodgkin\u2019s lymphoma. Hematol Oncol Clin North Am 22(5): 997\u20131005, x","journal-title":"Hematology\/Oncology Clinics of North America"},{"issue":"7","key":"4_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ajh.24076","volume":"90","author":"JO Armitage","year":"2015","unstructured":"Armitage JO (2015) The aggressive peripheral T-cell lymphomas: 2015. Am J Hematol 90(7):665\u2013673","journal-title":"Am J Hematol"},{"issue":"2","key":"4_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.hoc.2016.11.003","volume":"31","author":"TM Dhawale","year":"2017","unstructured":"Dhawale TM, Shustov AR (2017) Autologous and allogeneic hematopoietic cell transplantation in peripheral T\/NK-cell lymphomas: a histology-specific review. Hematol Oncol Clin North Am 31(2):335\u2013357","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"4_CR8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2016.0117","volume":"14","author":"SM Horwitz","year":"2016","unstructured":"Horwitz SM et al (2016) NCCN guidelines insights: non-Hodgkin\u2019s lymphomas, version 3.2016. J Natl Compr Cancer Netw 14(9):1067\u20131079","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"4_CR9","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11899-015-0291-0","volume":"10","author":"M Bellei","year":"2015","unstructured":"Bellei M et al (2015) The value and relevance of the T cell lymphoma registries and international collaborations: the case of COMPLETE and the T-cell project. Curr Hematol Malig Rep 10(4):448\u2013455","journal-title":"Curr Hematol Malig Rep"},{"key":"4_CR10","first-page":"1179545X1770586","volume":"10","author":"CAT Hildyard","year":"2017","unstructured":"Hildyard C et al (2017) Toward a biology-driven treatment strategy for peripheral T-cell lymphoma. Clin Med Insights Blood Disord 10:1179545X17705863","journal-title":"Clinical Medicine Insights: Blood Disorders"},{"issue":"9","key":"4_CR11","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1200\/JCO.2015.63.5540","volume":"34","author":"SV Adams","year":"2016","unstructured":"Adams SV, Newcomb PA, Shustov AR (2016) Racial patterns of peripheral T-cell lymphoma incidence and survival in the United States. J Clin Oncol 34(9):963\u2013971","journal-title":"J Clin Oncol"},{"issue":"12","key":"4_CR12","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD et al (2011) Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the international peripheral T-cell lymphoma project. Blood 117(12):3402\u20133408","journal-title":"Blood"},{"issue":"6","key":"4_CR13","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11899-016-0353-y","volume":"11","author":"A Phan","year":"2016","unstructured":"Phan A, Veldman R, Lechowicz MJ (2016) T-cell lymphoma epidemiology: the known and unknown. Curr Hematol Malig Rep 11(6):492\u2013503","journal-title":"Curr Hematol Malig Rep"},{"issue":"48","key":"4_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/jncimonographs\/lgu012","volume":"2014","author":"SS Wang","year":"2014","unstructured":"Wang SS et al (2014) Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph non-Hodgkin lymphoma subtypes project. J Natl Cancer Inst Monogr 2014(48):66\u201375","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"20","key":"4_CR15","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"issue":"2","key":"4_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.hoc.2016.11.009","volume":"31","author":"M Al-Zahrani","year":"2017","unstructured":"Al-Zahrani M, Savage KJ (2017) Peripheral T-cell lymphoma, not otherwise specified: a review of current disease understanding and therapeutic approaches. Hematol Oncol Clin North Am 31(2):189\u2013207","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"4_CR17","doi-asserted-by":"publisher","first-page":"djw248","DOI":"10.1093\/jnci\/djw248","volume":"109","author":"Carla Casulo","year":"2016","unstructured":"Casulo C et al (2017) T-cell lymphoma: recent advances in characterization and new opportunities for treatment. J Natl Cancer Inst 109(2)","journal-title":"Journal of the National Cancer Institute"},{"issue":"23","key":"4_CR18","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1200\/JCO.2017.72.6745","volume":"35","author":"JP Leonard","year":"2017","unstructured":"Leonard JP, Martin P, Roboz GJ (2017) Practical implications of the 2016 revision of the World Health Organization classification of lymphoid and myeloid neoplasms and acute leukemia. J Clin Oncol 35(23):2708\u20132715","journal-title":"J Clin Oncol"},{"issue":"6","key":"4_CR19","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1111\/bjh.14473","volume":"176","author":"N Schmitz","year":"2017","unstructured":"Schmitz N, de Leval L (2017) How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future. Br J Haematol 176(6):851\u2013866","journal-title":"Br J Haematol"},{"issue":"1","key":"4_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pathog.2016.02.002","volume":"3","author":"F Maura","year":"2016","unstructured":"Maura F (2016) Biology of peripheral T cell lymphomas\u2014not otherwise specified: is something finally happening? Pathogenesis 3(1):9\u201318","journal-title":"Pathogenesis"},{"issue":"3","key":"4_CR21","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.critrevonc.2010.07.007","volume":"79","author":"KJ Savage","year":"2011","unstructured":"Savage KJ et al (2011) Peripheral T-cell lymphoma\u2013not otherwise specified. Crit Rev Oncol Hematol 79(3):321\u2013329","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"4_CR22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/bjh.12255","volume":"161","author":"N Yoshida","year":"2013","unstructured":"Yoshida N et al (2013) Primary peripheral T-cell lymphoma, not otherwise specified of the thyroid with autoimmune thyroiditis. Br J Haematol 161(2):214\u2013223","journal-title":"Br J Haematol"},{"issue":"6","key":"4_CR23","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1080\/10428190902926981","volume":"50","author":"E Geissinger","year":"2009","unstructured":"Geissinger E et al (2009) CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies. Leuk Lymphoma 50(6):1010\u20131016","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"4_CR24","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","volume":"145","author":"L Jiang","year":"2009","unstructured":"Jiang L et al (2009) Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 145(2):173\u2013179","journal-title":"Br J Haematol"},{"issue":"4","key":"4_CR25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","volume":"17","author":"ED Hsi","year":"2017","unstructured":"Hsi ED et al (2017) Analysis of peripheral T-cell lymphoma diagnostic workup in the United States. Clin Lymphoma Myeloma Leuk 17(4):193\u2013200","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"4_CR26","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11899-015-0289-7","volume":"10","author":"M Sakata-Yanagimoto","year":"2015","unstructured":"Sakata-Yanagimoto M, Chiba S (2015) Molecular pathogenesis of peripheral T cell lymphoma. Curr Hematol Malig Rep 10(4):429\u2013437","journal-title":"Curr Hematol Malig Rep"},{"issue":"19","key":"4_CR27","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1182\/blood-2013-11-536359","volume":"123","author":"J Iqbal","year":"2014","unstructured":"Iqbal J et al (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood 123(19):2915\u20132923","journal-title":"Blood"},{"issue":"19","key":"4_CR28","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1182\/blood-2014-02-555763","volume":"123","author":"L Leval de","year":"2014","unstructured":"de Leval L, Gaulard P (2014) Cellular origin of T-cell lymphomas. Blood 123(19):2909\u20132910","journal-title":"Blood"},{"issue":"11","key":"4_CR29","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1182\/blood-2006-10-055145","volume":"109","author":"L Leval de","year":"2007","unstructured":"de Leval L et al (2007) The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109(11):4952\u20134963","journal-title":"Blood"},{"issue":"2","key":"4_CR30","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s00277-014-2188-8","volume":"94","author":"P Xu","year":"2015","unstructured":"Xu P et al (2015) Analysis of prognostic factors and comparison of prognostic scores in peripheral T cell lymphoma, not otherwise specified: a single-institution study of 105 Chinese patients. Ann Hematol 94(2):239\u2013247","journal-title":"Ann Hematol"},{"issue":"2","key":"4_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/annonc\/mdq359","volume":"22","author":"G Gutierrez-Garcia","year":"2011","unstructured":"Gutierrez-Garcia G et al (2011) Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol 22(2):397\u2013404","journal-title":"Ann Oncol"},{"issue":"10","key":"4_CR32","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F et al (2014) Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124(10):1570\u20131577","journal-title":"Blood"},{"issue":"8","key":"4_CR33","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/ijc.30566","volume":"140","author":"BM Haverkos","year":"2017","unstructured":"Haverkos BM et al (2017) Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. Int J Cancer 140(8):1899\u20131906","journal-title":"Int J Cancer"},{"issue":"4","key":"4_CR34","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s11899-015-0292-z","volume":"10","author":"AA Gru","year":"2015","unstructured":"Gru AA et al (2015) The Epstein-Barr Virus (EBV) in T cell and NK cell lymphomas: time for a reassessment. Curr Hematol Malig Rep 10(4):456\u2013467","journal-title":"Curr Hematol Malig Rep"},{"key":"4_CR35","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1038\/bcj.2014.34","volume":"4","author":"R Briski","year":"2014","unstructured":"Briski R et al (2014) The role of front-line anthracycline-containing chemotherapy regimens in peripheral T-cell lymphomas. Blood Cancer J 4:e214","journal-title":"Blood Cancer J"},{"key":"4_CR36","doi-asserted-by":"publisher","first-page":"623924","DOI":"10.5402\/2011\/623924","volume":"2011","author":"AN Abouyabis","year":"2011","unstructured":"Abouyabis AN et al (2011) A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011:623924","journal-title":"ISRN Hematol"},{"issue":"18","key":"4_CR37","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz N et al (2010) Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116(18):3418\u20133425","journal-title":"Blood"},{"issue":"1","key":"4_CR38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-005-0136-y","volume":"58","author":"JG Kim","year":"2006","unstructured":"Kim JG et al (2006) CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 58(1):35\u201339","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4_CR39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/cncr.27733","volume":"119","author":"D Mahadevan","year":"2013","unstructured":"Mahadevan D et al (2013) Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. Cancer 119(2):371\u2013379","journal-title":"Cancer"},{"issue":"4","key":"4_CR40","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/bjh.13855","volume":"172","author":"RH Advani","year":"2016","unstructured":"Advani RH et al (2016) A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. Br J Haematol 172(4):535\u2013544","journal-title":"Br J Haematol"},{"issue":"2","key":"4_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1365-2141.2010.08329.x","volume":"151","author":"A Simon","year":"2010","unstructured":"Simon A et al (2010) Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP\/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 151(2):159\u2013166","journal-title":"Br J Haematol"},{"issue":"10","key":"4_CR42","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1002\/cncr.20999","volume":"103","author":"MP Escalon","year":"2005","unstructured":"Escalon MP et al (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer 103(10):2091\u20132098","journal-title":"Cancer"},{"issue":"6","key":"4_CR43","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clml.2013.07.005","volume":"13","author":"N Mehta","year":"2013","unstructured":"Mehta N et al (2013) A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Clin Lymphoma Myeloma Leuk 13(6):664\u2013670","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4_CR44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1182\/asheducation-2015.1.550","volume":"2015","author":"AW Beaven","year":"2015","unstructured":"Beaven AW, Diehl LF (2015) Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma. Hematology Am Soc Hematol Educ Program 2015:550\u2013558","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"25","key":"4_CR45","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith SM et al (2013) Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol 31(25):3100\u20133109","journal-title":"J Clin Oncol"},{"issue":"25","key":"4_CR46","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F et al (2012) Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30(25):3093\u20133099","journal-title":"J Clin Oncol"},{"issue":"5","key":"4_CR47","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","volume":"40","author":"S Feyler","year":"2007","unstructured":"Feyler S et al (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transpl 40(5):443\u2013450","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"4_CR48","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","volume":"25","author":"JS Abramson","year":"2014","unstructured":"Abramson JS et al (2014) Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol 25(11):2211\u20132217","journal-title":"Ann Oncol"},{"issue":"12","key":"4_CR49","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","volume":"14","author":"J Rodriguez","year":"2003","unstructured":"Rodriguez J et al (2003) High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 14(12):1768\u20131775","journal-title":"Ann Oncol"},{"issue":"12","key":"4_CR50","first-page":"1372","volume":"88","author":"J Rodriguez","year":"2003","unstructured":"Rodriguez J et al (2003) High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Haematologica 88(12):1372\u20131377","journal-title":"Haematologica"},{"issue":"1","key":"4_CR51","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.bbmt.2008.11.010","volume":"15","author":"DH Yang","year":"2009","unstructured":"Yang DH et al (2009) Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biol Blood Marrow Transpl 15(1):118\u2013125","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"4_CR52","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/leu.2014.79","volume":"28","author":"P Corradini","year":"2014","unstructured":"Corradini P et al (2014) Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia 28(9):1885\u20131891","journal-title":"Leukemia"},{"key":"4_CR53","unstructured":"Schmitz N et al (2015) Allogeneic or autologous transplantation as first-line therapy for younger patients with peripheral T-cell lymphoma: results of the interim analysis of the AATT trial. J Clin Oncol 33(15): 8507"},{"issue":"5","key":"4_CR54","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","volume":"21","author":"A Beitinjaneh","year":"2015","unstructured":"Beitinjaneh A et al (2015) Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transpl 21(5):855\u2013859","journal-title":"Biol Blood Marrow Transpl"},{"issue":"7","key":"4_CR55","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1093\/annonc\/mdr140","volume":"22","author":"C Hosing","year":"2011","unstructured":"Hosing C, Champlin RE (2011) Stem-cell transplantation in T-cell non-Hodgkin\u2019s lymphomas. Ann Oncol 22(7):1471\u20131477","journal-title":"Ann Oncol"},{"issue":"6","key":"4_CR56","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1046\/j.1365-2141.2003.04203.x","volume":"120","author":"KW Song","year":"2003","unstructured":"Song KW et al (2003) Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 120(6):978\u2013985","journal-title":"Br J Haematol"},{"issue":"17","key":"4_CR57","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1182\/blood-2013-12-516245","volume":"123","author":"AJ Moskowitz","year":"2014","unstructured":"Moskowitz AJ, Lunning MA, Horwitz SM (2014) How I treat the peripheral T-cell lymphomas. Blood 123(17):2636\u20132644","journal-title":"Blood"},{"issue":"11","key":"4_CR58","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","volume":"22","author":"P Corradini","year":"2004","unstructured":"Corradini P et al (2004) Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin\u2019s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 22(11):2172\u20132176","journal-title":"J Clin Oncol"},{"issue":"16","key":"4_CR59","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V et al (2013) Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol 31(16):1970\u20131976","journal-title":"J Clin Oncol"},{"issue":"2","key":"4_CR60","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.hoc.2016.11.002","volume":"31","author":"E Marchi","year":"2017","unstructured":"Marchi E, Raufi AG, O\u2019Connor OA (2017) Novel agents in the treatment of relapsed or refractory peripheral T-cell lymphoma. Hematol Oncol Clin North Am 31(2):359\u2013375","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"4_CR61","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL et al (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21(4):860\u2013863","journal-title":"Ann Oncol"},{"issue":"4","key":"4_CR62","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/annonc\/mds643","volume":"24","author":"M Dreyling","year":"2013","unstructured":"Dreyling M et al (2013) ESMO consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 24(4):857\u2013877","journal-title":"Ann Oncol"},{"issue":"8","key":"4_CR63","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26(8):1766\u20131771","journal-title":"Ann Oncol"},{"issue":"4","key":"4_CR64","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/2040620712445330","volume":"3","author":"E Marchi","year":"2012","unstructured":"Marchi E, O\u2019Connor OA (2012) Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Ther Adv Hematol 3(4):227\u2013235","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"4_CR65","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.det.2015.05.009","volume":"33","author":"GS Wood","year":"2015","unstructured":"Wood GS, Wu J (2015) Methotrexate and pralatrexate. Dermatol Clin 33(4):747\u2013755","journal-title":"Dermatol Clin"},{"issue":"3","key":"4_CR66","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","volume":"143","author":"P Bose","year":"2014","unstructured":"Bose P, Dai Y, Grant S (2014) Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther 143(3):323\u2013336","journal-title":"Pharmacol Ther"},{"issue":"4","key":"4_CR67","doi-asserted-by":"publisher","first-page":"458","DOI":"10.4161\/mabs.20230","volume":"4","author":"NW Donk van de","year":"2012","unstructured":"van de Donk NW, Dhimolea E (2012) Brentuximab vedotin. MAbs 4(4):458\u2013465","journal-title":"MAbs"},{"issue":"6","key":"4_CR68","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3109\/10428194.2014.963078","volume":"56","author":"R Briski","year":"2015","unstructured":"Briski R et al (2015) Survival in patients with limited-stage peripheral T-cell lymphomas. Leuk Lymphoma 56(6):1665\u20131670","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"4_CR69","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3109\/0284186X.2015.1118656","volume":"55","author":"R Gurion","year":"2016","unstructured":"Gurion R et al (2016) Central nervous system involvement in T-cell lymphoma: a single center experience. Acta Oncol 55(5):561\u2013566","journal-title":"Acta Oncol"},{"issue":"26","key":"4_CR70","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1182\/blood-2010-02-266890","volume":"115","author":"B Pro","year":"2010","unstructured":"Pro B, Perini G (2010) Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood 115(26):5427","journal-title":"Blood"},{"issue":"1","key":"4_CR71","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3348\/kjr.2017.18.1.71","volume":"18","author":"HS Park","year":"2017","unstructured":"Park HS et al (2017) T-cell non-Hodgkin lymphomas: spectrum of disease and the role of imaging in the management of common subtypes. Korean J Radiol 18(1):71\u201383","journal-title":"Korean J Radiol"}],"container-title":["Cancer Treatment and Research","T-Cell and NK-Cell Lymphomas"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-99716-2_4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,12,30]],"date-time":"2018-12-30T11:38:52Z","timestamp":1546169932000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-319-99716-2_4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,31]]},"ISBN":["9783319997155","9783319997162"],"references-count":71,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-99716-2_4","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,31]]}}}